Quantum‑Si Incorporated announced a multi‑city roadshow to showcase its next‑generation Proteus protein‑sequencing platform. The first stop is scheduled for April 7 2026 in Seattle, followed by Washington, D.C. on April 30 and Houston on May 5, with additional dates to be added as the launch window approaches.
The Proteus platform is designed to deliver unprecedented sequencing throughput. While the company has not confirmed an 80‑million‑feature consumable chip, it has stated that the platform will support up to 160 million features per instrument run and will expand amino‑acid coverage from the current 18 to all 20 amino acids by the end of 2026. These capabilities are intended to give Proteus a competitive edge over existing single‑molecule protein detection systems.
Quantum‑Si’s most recent quarterly results provide context for the roadshow’s timing. In Q4 2025 the company generated $451,000 in revenue—$310,900 below the consensus estimate of $761,900—yet posted earnings of –$0.08 per share, beating the –$0.14 expectation by $0.06. The miss in revenue was largely driven by lower demand for consumables and a shift toward higher‑margin instrument sales, while the EPS beat reflected disciplined cost management and a favorable product‑mix shift. Gross margin contracted to 27% from 47% for the full year, a compression attributed to a higher proportion of consumable revenue and inventory adjustments. The company’s cash balance of $215.8 million, as of December 31 2025, is expected to fund operations through Q2 2028.
Jeff Hawkins, President and CEO, emphasized the strategic importance of the roadshow: “We are excited to kick off this important pre‑launch program to expand the breadth and depth of customer awareness for both Proteus and protein sequencing. We believe this is an important program since Proteus is expected to far exceed Platinum Pro’s capabilities, and this outreach will help us reach customers we were not previously able to reach with Platinum Pro.” He added that 2026 is a deliberate transition year, prioritizing long‑term platform adoption over short‑term revenue maximization.
Investors reacted negatively to the Q4 2025 results, citing the revenue miss and ongoing net losses as concerns. The market’s focus on the company’s cash burn and the lack of immediate revenue from the new platform has tempered enthusiasm for the roadshow, even as management projects a strong pipeline of early adopters that could drive consumable revenue once the platform goes to market.
The roadshow is a key component of Quantum‑Si’s strategy to build a pipeline of early adopters and generate consumable revenue in the first year after launch. While the company remains in a pre‑revenue stage for the Proteus platform, the event signals a shift toward commercialization and provides a platform for the company to demonstrate its technology’s capabilities to a broad audience of academic, clinical, and industrial researchers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.